Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.
Danny Rischin, MD
Advertisement
Medical oncologist, clinician researcher, Peter McCallum Cancer Centre.
Articles by Danny Rischin, MD
Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant treatment approach for patients with locally advanced cutaneous squamous cell carcinoma (CSCC).
Cemiplimab significantly enhances disease-free survival in high-risk cSCC patients, reducing recurrence and metastasis risks, according to findings presented at ASCO.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
3
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
4
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
5